SCM Pharma Limited Appoints New Director

UK-based contract development and manufacturing organisation (CDMO) SCM Pharma has strengthened its senior management team by recruiting a high-profile director.

Paul Bradley joins the award-winning specialist manufacturer as Operations Director and will also sit on the company's board. Formally of Hospira Aseptic Services, he will now be responsible for all operational activities at SCM Pharma including production, warehouse and facilities.

In keeping with the company's core area of competence, Paul brings exceptional experience of clinical trial and commercial manufacturing involving sterile products. He is the latest in a string of new senior appointments by the organisation who added quality professional Mark Edwards as Quality Assurance Director earlier this year.

Dianne Sharp, managing director at SCM Pharma, said: "We are delighted to have Paul join the team as he brings a very distinct and important set of skills relating to operations to the management team.

"As the company continues to grow and handle more and more products, it is vital we are reliably planning, manufacturing and delivering drugs to our clients whether they are for clinical trials or commercial market supply.

"Paul will no doubt be a great addition to the team and will play a significant role in overseeing and supporting client projects across both of our sites," added Dianne.

With over 15 years' experience of research, development and manufacturing, Paul moved into the sterile manufacturing area in 2007. With a BSc (Hons) in Chemistry from Durham University and a Management Diploma at Loughborough College, he will play a pivotal role in developing robust and efficient processes and systems at SCM Pharma on technically challenging products.

He said: "As soon as I became aware of the opportunity at SCM Pharma, I was immediately interested as I'd heard very good things about the company's set-up, vision and its willingness to invest in people, technology and facilities.

"In the short time I have been here I have already been impressed by the commitment to continuously improve and the can-do attitude to delivering to customers and patients.

"I am very excited by the prospect of working closely with the team and clients to develop and deliver technically challenging products that will benefit all stakeholders and improve patient health."

SCM Pharma specialises in the sterile production of products for clinical trials along with the supply of licensed drugs in niche markets. It will soon open the doors of its new commercial facility that will reinforce its expertise in vial, ampoule and syringe filling, particularly when dealing with potent products requiring high containment.

www.scmpharma.com | [email protected]

Suggested Articles

All subjects had lower extremity weakness after receiving antisense oligonucleotide GTX-102, leading Ultragenyx to pause the study.

Investigators stopped enrolling patients in the study after finding LY-CoV555 is unlikely to improve outcomes in the studied patient population.

It’s the final nail in the coffin for Catabasis’ Duchenne muscular dystrophy hopeful as edasalonexent has once again failed to deliver.